Yeast

Evolva pays €550,000 for Fluxome resveratrol business

Evolva pays €550,000 for Fluxome resveratrol business

By Shane Starling

Swiss biotech firm Evolva has bought failing Fluxome’s, yeast-derived resveratrol business for about €550,000 in cash and shares, but says it has no interest in the remaining omega-3 business being sold by sealed auction.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All